IGC Pharma Private Investor Briefing - NYC

🌟 Dear Investors,
Join us for a private investor briefing hosted by Opus8 and the New York Private Equity Forum (NYPEF) featuring IGC Pharma (NYSE American: IGC), a pioneering clinical-stage biotechnology and AI company dedicated to developing innovative therapeutics and predictive intelligence platforms aimed at combatting Alzheimer’s disease.

Company Overview

IGC Pharma is actively working on groundbreaking solutions for Alzheimer’s disease, with its lead therapeutic candidate, IGC-AD1, currently in a Phase 2 clinical trial targeting agitation—a major unmet need impacting millions globally.

Key Highlights

• 🚀 Phase 2 clinical trial nearing completion with multiple anticipated catalysts in the next 4–9 months
• 🌍 Addressing a significant unmet need in Alzheimer’s disease, affecting over 40 million people worldwide
• 💡 Lead therapeutic candidate aims to enhance current treatment options
• 🤖 AI-powered healthcare platform presenting additional growth opportunities beyond therapeutics
• 🔬 Positioned at the forefront of biotechnology, artificial intelligence, and aging-related healthcare innovation
• 📈 Publicly traded with a current valuation notably below peers in the Alzheimer's biotech sector

Event Details:

📅 Date: July 14
🕔 Time: 5:30 PM - 7:30 PM
📍 Location: Tony's Di Napoli, 1081 3rd Ave, New York, NY 10065

Please note this meeting is exclusively for DIRECT and ACTIVE Accredited investors. It is essential that all RSVPs are pre-registered through this site with investor criteria completed. Each RSVP is subject to review and approval. Following registration, a confirmation email and calendar invite will be sent.

📧 Request investor materials by contacting Skylar Rallison.
🔗 RSVP here

Thanks much and all the best,
Tien Wong
CEO
Opus8, Inc.
✉️ twong@opus8.com